Compare INTZ & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | DARE |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.0M | 24.0M |
| IPO Year | 2020 | N/A |
| Metric | INTZ | DARE |
|---|---|---|
| Price | $1.49 | $1.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 128.6K | 93.1K |
| Earning Date | 11-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,290,000.00 | N/A |
| Revenue This Year | $38.09 | $3,924.12 |
| Revenue Next Year | $27.59 | $8,523.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.49 | N/A |
| 52 Week Low | $0.35 | $1.61 |
| 52 Week High | $7.34 | $9.19 |
| Indicator | INTZ | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 46.20 |
| Support Level | $1.32 | $1.64 |
| Resistance Level | $1.47 | $1.86 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 80.56 | 54.07 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The group offers customers to access its threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol (IP) addresses. The company's product consists of On-Premise Network Protection, Cyber Threat Consulting, Cloud Network Security, and Endpoint Protection. Its solutions are INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. Its end-user customers include the U.S. federal government, state and local government entities, large and diversified conglomerates, and manufacturing entities.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.